Need an EAP granted for stone growth.
Need the old data to support the single arm, need the old data excluded to validate the current profile. Not ideal but the FDA have been holding our hand crossing, not the committee.
Approved with a post-marketing observational study like Tecartus. (IMO)
Ann: Update on Scheduled FDA Advisory Committee Meeting, page-66
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.025(2.45%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.04 | 99.5¢ | $4.379M | 4.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 163238 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 19700 | 2 |
View Market Depth
| Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |